19LBA Docetaxel (Doc) +/− zoledronic acid (ZA) for hormone-naive prostate cancer: First overall survival results from STAMPEDE & treatment effects within subgroups (NCT00268476). Issue 3 (September 2015) - James, N.D.; Sydes, M.R.; Mason, M.D.; Clarke, N.W.; Dearnaley, D.P.; Spears, M.R.; Millman, R.; Parker, C.C.; Ritchie, A.W.S.; Russell, J.M.; Staffurth, J.; Jones, R.J.; et al.